-
1
-
-
33846181370
-
Sunitinib versus interferon alfa in metastatic renal-cell carcinoma
-
R.J. Motzer, T.E. Hutson, and P. Tomczak et al. Sunitinib versus interferon alfa in metastatic renal-cell carcinoma N Engl J Med 356 2007 115 124
-
(2007)
N Engl J Med
, vol.356
, pp. 115-124
-
-
Motzer, R.J.1
Hutson, T.E.2
Tomczak, P.3
-
2
-
-
62449186539
-
Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma
-
B. Escudier, C. Szczylik, and T.E. Hutson et al. Randomized phase II trial of first-line treatment with sorafenib versus interferon Alfa-2a in patients with metastatic renal cell carcinoma J Clin Oncol 27 2009 1280 1289
-
(2009)
J Clin Oncol
, vol.27
, pp. 1280-1289
-
-
Escudier, B.1
Szczylik, C.2
Hutson, T.E.3
-
3
-
-
77949890945
-
Pazopanib in locally advanced or metastatic renal cell carcinoma: Results of a randomized phase III trial
-
C.N. Sternberg, I.D. Davis, and J. Mardiak et al. Pazopanib in locally advanced or metastatic renal cell carcinoma: results of a randomized phase III trial J Clin Oncol 28 2010 1061 1068
-
(2010)
J Clin Oncol
, vol.28
, pp. 1061-1068
-
-
Sternberg, C.N.1
Davis, I.D.2
Mardiak, J.3
-
4
-
-
56749161699
-
Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206
-
B.I. Rini, S. Halabi, and J.E. Rosenberg et al. Bevacizumab plus interferon alfa compared with interferon alfa monotherapy in patients with metastatic renal cell carcinoma: CALGB 90206 J Clin Oncol 26 2008 5422 5428
-
(2008)
J Clin Oncol
, vol.26
, pp. 5422-5428
-
-
Rini, B.I.1
Halabi, S.2
Rosenberg, J.E.3
-
5
-
-
77952300540
-
Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): Final analysis of overall survival
-
B. Escudier, J. Bellmunt, and S. Negrier et al. Phase III trial of bevacizumab plus interferon alfa-2a in patients with metastatic renal cell carcinoma (AVOREN): final analysis of overall survival J Clin Oncol 28 2010 2144 2150
-
(2010)
J Clin Oncol
, vol.28
, pp. 2144-2150
-
-
Escudier, B.1
Bellmunt, J.2
Negrier, S.3
-
6
-
-
84867755853
-
Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial
-
(abstract 4501)
-
R.J. Motzer, D. Nosov, and T. Eisen et al. Tivozanib versus sorafenib as initial targeted therapy for patients with advanced renal cell carcinoma: Results from a phase III randomized, open-label, multicenter trial J Clin Oncol 30 Suppl 15 2012 (abstract 4501)
-
(2012)
J Clin Oncol
, vol.30
, Issue.SUPPL. 15
-
-
Motzer, R.J.1
Nosov, D.2
Eisen, T.3
-
7
-
-
34249779568
-
Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma
-
G. Hudes, M. Carducci, and P. Tomczak et al. Temsirolimus, interferon alfa, or both for advanced renal-cell carcinoma N Engl J Med 356 2007 2271 2281
-
(2007)
N Engl J Med
, vol.356
, pp. 2271-2281
-
-
Hudes, G.1
Carducci, M.2
Tomczak, P.3
-
8
-
-
82755183572
-
Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): A randomized phase 3 trial
-
B.I. Rini, B. Escudier, and P. Tomczak et al. Comparative effectiveness of axitinib versus sorafenib in advanced renal cell carcinoma (AXIS): a randomized phase 3 trial Lancet 378 2011 1931 1939
-
(2011)
Lancet
, vol.378
, pp. 1931-1939
-
-
Rini, B.I.1
Escudier, B.2
Tomczak, P.3
-
9
-
-
48649107474
-
Efficacy of everolimus in advanced renal cell carcinoma: A double-blind, randomized, placebo-controlled phase III trial
-
R.J. Motzer, B. Escudier, and S. Oudard et al. Efficacy of everolimus in advanced renal cell carcinoma: a double-blind, randomized, placebo-controlled phase III trial Lancet 372 2008 449 456
-
(2008)
Lancet
, vol.372
, pp. 449-456
-
-
Motzer, R.J.1
Escudier, B.2
Oudard, S.3
-
10
-
-
84876952724
-
Temsirolimus vs sorafenib as second-line therapy in metastatic renal cell carcinoma: Results from the INTORSECT trial
-
(Abstract LBA22-PR)
-
T. Hutson, B. Escudier, and E. Esteban et al. Temsirolimus vs. sorafenib as second-line therapy in metastatic renal cell carcinoma: results from the INTORSECT trial Ann Oncol 23 suppl 9 2012 (Abstract LBA22-PR)
-
(2012)
Ann Oncol
, vol.23
, Issue.SUPPL. 9
-
-
Hutson, T.1
Escudier, B.2
Esteban, E.3
-
11
-
-
67349163859
-
Sequential sorafenib and sunitinib for renal cell carcinoma
-
M.P. Sablin, S. Negrier, and A. Ravaud et al. Sequential sorafenib and sunitinib for renal cell carcinoma J Urol 182 2009 29 34
-
(2009)
J Urol
, vol.182
, pp. 29-34
-
-
Sablin, M.P.1
Negrier, S.2
Ravaud, A.3
-
12
-
-
58949092548
-
Sequential therapy with sorafenib and sunitinib in renal cell carcinoma
-
A.Z. Dudek, J. Zolnierek, A. Dham, B.R. Lindgren, and C. Szczylik Sequential therapy with sorafenib and sunitinib in renal cell carcinoma Cancer 115 2009 61 67
-
(2009)
Cancer
, vol.115
, pp. 61-67
-
-
Dudek, A.Z.1
Zolnierek, J.2
Dham, A.3
Lindgren, B.R.4
Szczylik, C.5
-
13
-
-
70349388719
-
Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma
-
B.I. Rini, G. Wilding, and G. Hudes et al. Phase II study of axitinib in sorafenib-refractory metastatic renal cell carcinoma J Clin Oncol 27 2009 4462 4468
-
(2009)
J Clin Oncol
, vol.27
, pp. 4462-4468
-
-
Rini, B.I.1
Wilding, G.2
Hudes, G.3
-
14
-
-
78650383149
-
Temsirolimus in VEGF-refractory metastatic renal cell carcinoma
-
M.J. Mackenzie, B.I. Rini, and P. Elson et al. Temsirolimus in VEGF-refractory metastatic renal cell carcinoma Ann Oncol 22 2010 145 148
-
(2010)
Ann Oncol
, vol.22
, pp. 145-148
-
-
Mackenzie, M.J.1
Rini, B.I.2
Elson, P.3
-
15
-
-
78649568788
-
Sunitinib rechallenge in metastatic renal cell carcinoma patients
-
I.N. Zama, T.E. Hutson, and P. Elson et al. Sunitinib rechallenge in metastatic renal cell carcinoma patients Cancer 116 2010 5400 5406
-
(2010)
Cancer
, vol.116
, pp. 5400-5406
-
-
Zama, I.N.1
Hutson, T.E.2
Elson, P.3
-
16
-
-
77955470097
-
Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor targeted therapy
-
M.M. Vickers, T.K. Choueiri, and M. Rogers et al. Clinical outcome in metastatic renal cell carcinoma patients after failure of initial vascular endothelial growth factor targeted therapy Urology 76 2010 430 434
-
(2010)
Urology
, vol.76
, pp. 430-434
-
-
Vickers, M.M.1
Choueiri, T.K.2
Rogers, M.3
-
17
-
-
79960369634
-
Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): Clinical characteristics, risk factors, and subsequent therapy
-
(abstract 305)
-
D.Y. Heng, M. MacKenzie, and U.N. Vaishampayan et al. Primary anti-VEGF-refractory metastatic renal cell carcinoma (mRCC): clinical characteristics, risk factors, and subsequent therapy J Clin Oncol 29 Suppl 7 2011 (abstract 305)
-
(2011)
J Clin Oncol
, vol.29
, Issue.SUPPL. 7
-
-
Heng, D.Y.1
Mackenzie, M.2
Vaishampayan, U.N.3
-
18
-
-
73349084973
-
Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: Results from a large, multicenter study
-
D.Y. Heng, W. Xie, and M.M. Regan et al. Prognostic factors for overall survival in patients with metastatic renal cell carcinoma treated with vascular endothelial growth factor-targeted agents: results from a large, multicenter study J Clin Oncol 27 2009 5794 5799
-
(2009)
J Clin Oncol
, vol.27
, pp. 5794-5799
-
-
Heng, D.Y.1
Xie, W.2
Regan, M.M.3
-
19
-
-
37849001813
-
Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma
-
T.K. Choueiri, A. Plantade, and P. Elson et al. Efficacy of sunitinib and sorafenib in metastatic papillary and chromophobe renal cell carcinoma J Clin Oncol 26 2008 127 131
-
(2008)
J Clin Oncol
, vol.26
, pp. 127-131
-
-
Choueiri, T.K.1
Plantade, A.2
Elson, P.3
-
20
-
-
67651056360
-
Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies
-
J.P. Dutcher, P. de Souza, and D. McDermott et al. Effect of temsirolimus versus interferon-alpha on outcome of patients with advanced renal cell carcinoma of different tumor histologies Med Oncol 26 2009 202 209
-
(2009)
Med Oncol
, vol.26
, pp. 202-209
-
-
Dutcher, J.P.1
De Souza, P.2
McDermott, D.3
|